20 miliardi di euro l’anno: i costi per il cancro in Italia – Prevenzione attiva, la vera arma vincente
The analysis of a single cancer driver has a very low value in terms of prevention, and none in terms of prediction. The added value provided by the BIOSCIENCE GENOMICS proposal is the integrated analysis of at least 4 to 5 different cancer drivers, which will enable very sophisticated profiling based on multi-layer, multi-target and multi-biomarker data. Currently, BIOSCIENCE GENOMICS is the first and only company in the world to introduce the Cancer Driver Interception model as a valuable alternative to Cancer Early Detection, in the realm of cancer prevention. Early detection by means of cfDNA analysis still remains an ambitious goal. On the other hand, monitoring the overall genomic instability in healthy individuals could help identify those in need of early access to screening prevention programs. The combined analysis of multiple cancer drivers enables the most detailed level of profiling ever offered to healthy people aiming at reducing their risk of cancer development.
